Manufacturing NewsTEG DailyNovember 22, 2026

November 22, 2026 · Boone County · Story 3 of 5

Eli Lilly's GLP-1 Surge Backs the $4.5 Billion Lebanon Build-Out

Eli Lilly's Q2 2026 revenue rose 48% to $22.97 billion, with Mounjaro at $9.94 billion and Zepbound at $4.93 billion combining for 65% of total sales. The company raised full-year guidance to $85-87 billion on that volume. That demand is the backing behind Lilly's $4.5 billion Indiana manufacturing commitment anchored at the Lebanon LEAP District, expected to become the largest active pharmaceutical ingredient production facility built in the United States. Lilly holds roughly 60% of the U.S. GLP-1 market against Novo Nordisk's 40%, but Novo's oral Wegovy pill reached pharmacies four months ahead of Lilly's Foundayo and has already topped 3 million U.S. prescriptions, while Foundayo brought in just $98 million and missed Q3 estimates by $44 million. Lilly's follow-on drug, retatrutide, is waiting on an FDA decision over whether it qualifies as a biologic with 12 years of exclusivity or a small molecule with 5, a ruling due around the same time as Lilly's targeted Q1 2027 filing.

Impact
Lilly now holds roughly 60% of the U.S. GLP-1 market versus Novo Nordisk's 40%, but Novo's oral Wegovy pill beat Lilly's Foundayo to market by four months and already topped 3 million U.S. prescriptions, while Foundayo generated just $98 million and missed Q3 estimates by $44 million, meaning the Lebanon build-out is defending an injectable lead while Lilly plays catch-up on the oral front. Lilly's retatrutide BLA filing, targeted for Q1 2027, is also caught in an unresolved FDA classification fight over whether it's a biologic (12-year exclusivity) or small molecule (5-year exclusivity), a decision that could delay the filing and affect how long Lebanon's tirzepatide ramp needs to hold current volumes.
Watch
The FDA's classification decision on retatrutide (biologic vs. small molecule) and Lilly's targeted Q1 2027 BLA submission, both of which affect the Indiana manufacturing ramp timeline.
For the huddle

As Lilly's Lebanon build-out pulls in skilled trades and QA talent across the Indiana-Ohio corridor, are we positioned to compete for that same labor pool, or are we about to get squeezed by it?

Panduit and John Deere are adding warehouse and logistics jobs in Lake County, Lilly's Lebanon campus is pulling skilled trades and QA talent across the Indiana-Ohio corridor, and Lorain County's chip program shows what happens when training output outpaces a facility's actual opening date. If any of those labor pools overlap with yours, it's worth checking your own pipeline before the gap shows up on a shift schedule.

Sources

  1. Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B · tradingkey.com

Earlier coverage

From the brief, November 22, 2026

  1. 7th Circuit Shields High Performance Alloys' Insurer After Windfall Worker's Death
  2. Panduit's $76.5 Million Merrillville Investment Turns Illinois Losses Into Lake County Gains
  3. Eli Lilly's GLP-1 Surge Backs the $4.5 Billion Lebanon Build-Out
  4. Ohio's Chip Worker Pipeline Faces a Timing Mismatch Before Intel Even Opens
  5. Google Pays $10.8 Million to Jump Columbus's Transmission Queue, A Template AEP's Indiana Utility Could Replicate

The whole day’s brief →

This story

Related

Manufacturers Energy Grant Program

Free for Boone County manufacturers

Boone County manufacturers receive free, ongoing energy auditing and cost control that reduces their energy bills and keeps them low, month after month. Every line item checked and validated, every opportunity found comes with a step-by-step guide to capture it.

EDCs: sponsor this program and it carries your organization's name For economic developers →